Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mutant pHLIP-SIINFEKL
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- Peptides
- Administration
- Intravenous, Intratumoral
01
Overview
mutant pHLIP-SIINFEKL refers to a modified version of the pHLIP-SIINFEKL peptide conjugate, used as a negative control in preclinical research. The parent molecule, pHLIP-SIINFEKL, is designed to deliver the immunogenic SIINFEKL peptide (derived from ovalbumin) specifically to the acidic microenvironment of tumors using the pH low insertion peptide (pHLIP) platform. Once delivered, the SIINFEKL peptide is processed and presented via the MHC class I pathway to activate OT1 T cells. The mutant version involves alterations to either the pHLIP sequence (preventing pH-dependent membrane insertion) or the SIINFEKL sequence (preventing T-cell recognition), thereby serving to validate the specificity and mechanism of the wild-type conjugate in suppressing tumor growth. This research was conducted by investigators at Yale University and published in *Molecular Cancer Therapeutics* in 2025.
- Other names
- mutated pHLIP-SIINFEKL
02
Targets
OVA-specific TCR (Ovalbumin-specific T-cell receptor)pHe (Acidic tumor cell plasma membrane)H-2Kb-SIINFEKL (H-2 class I histocompatibility antigen, K-B alpha chain presenting SIINFEKL peptide)
Beyond the preview
Go deeper on mutant pHLIP-SIINFEKL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mutant pHLIP-SIINFEKL.